KIMS Krishna Institute of Medical Sciences Q3 FY25 results (Oct–Dec 2024) and concall
KIMS delivered strong year-on-year growth across revenue and EBITDA, driven by robust performance in its core Telangana and Andhra Pradesh clusters. While the quarter saw some sequential margin compression due to seasonal factors and initial losses from the Nashik facility, management remains aggressive on its expansion strategy. The company is successfully scaling its presence in Kerala and Maharashtra while maintaining a healthy balance sheet with debt-to-EBITDA targets below 2x.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 363 | 348 |
| EBITDA | 111 | 103 |
| Net profit | 72 | 76 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
